Callan JMB (CJMB) announced its role as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva Drug Delivery Systems, alongside Biostax Corp and SGP Holdings. The collaboration supports U.S.-based technology transfer, formulation development, and manufacturing scale-up for the JKB-122 immune restoration platform. Callan JMB’s role focuses on independent validation across manufacturing, quality systems, and supply chain operations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CJMB: